Avalo Therapeutics AVTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$78.26M-123% | -$35.13M-11.4% | -$31.54M+24.3% | -$41.66M+50.6% | ||
| $344K+104% | $169K+7.0% | $158K-4.8% | $166K-90.0% | ||
| $13.62M+133% | $5.85M+68.3% | $3.48M-54.0% | $7.55M-7.6% | ||
| -$51.46M-4.9% | -$49.06M-59.9% | -$30.68M— | —— | ||
| -$84.12M— | —— | —— | -$95K+15.9% | ||
| $14.59M— | —— | $25.04M— | —— | ||
| -$118.59M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Avalo Therapeutics generate?
- Avalo Therapeutics (AVTX) generated -$59.7M in operating cash flow over the trailing twelve months.
- Where does Avalo Therapeutics's cash flow data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
